title: Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
abstract: Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment.
authors.affiliation: Servicio de Farmacia, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Ramudo-Cela
authors.affiliation: Servicio de Farmacia, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Spain.
authors.forename: Jesús
authors.initials: J
authors.lastname: Balea-Filgueiras
authors.affiliation: Servicio de Farmacia, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Spain.
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Vizoso-Hermida
authors.affiliation: Servicio de Farmacia, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: Martín-Herranz
mesh_terms: D000069501:Abiraterone Acetate / Q000009:adverse effects / Q000627:therapeutic use; D000369:Aged, 80 and over; D000736:Androstenes / Q000009:adverse effects* / Q000627:therapeutic use; D018450:Disease Progression; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D056737:Safety-Based Drug Withdrawals / Q000639:trends*; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; D043823:Taxoids; D000077143:Docetaxel; D000069501:Abiraterone Acetate; C089740:abiraterone
keywords: Abiraterone; clinical management; metastatic castration-resistant prostate cancer; prostate cancer; safety